07:42 AM EDT, 05/17/2024 (MT Newswires) -- Autolus Therapeutics ( AUTL ) reported a Q1 loss Friday of $0.24 per share, wider than its loss of $0.23 per share a year earlier.

Analysts polled by Capital IQ expected a loss of $0.14 per share.

The biopharmaceutical company's licensing revenue for quarter ended March 31 was $10.09 million, up from $1.29 million a year earlier.

Cash and cash equivalents as of March 31 totalled $758.5 million, compared with $239.6 million on Dec. 31.

Autolus said with its current cash and cash equivalents and proceeds received from the strategic alliance with BioNTech and the private placement and underwritten equity financing, it is well capitalized to drive the full launch and commercialization of its cell therapy candidate obe-cel, and to advance its pipeline development plans, which includes providing runway to data in the first pivotal study of obe-cel in autoimmune disease.

Price: 4.1900, Change: +0.12, Percent Change: +2.95